Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Denny

Showing results (1-10 of 748) with videos related to

Pageof 75
Sort By:
Future Medicinal Chemistry|April 13, 2021
Inhibitors of F<sub>1</sub>F<sub>0</sub>-ATP synthase enzymes for the treatment of tuberculosis and cancerWilliam A Denny
Journal of Biomedicine & Biotechnology|April 11, 2003
Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)William A. Denny
The New Zealand Medical Journal|March 30, 2001
Turning off growth signals in tumours: a new approach to cancer chemotherapyW A Denny
Idrugs : the Investigational Drugs Journal|December 1, 2004
American Association for Cancer Research - 93rd Annual Meeting. Investigational kinase inhibitors. 6-10 April 2002, San Francisco, CA, USAWilliam A Denny
Expert Opinion on Investigational Drugs|July 5, 2005
Topoisomerase targeted agents - chemistry to chemotherapyW A Denny
The Lancet. Oncology|March 22, 2002
The role of hypoxia-activated prodrugs in cancer therapyW A Denny
Idrugs : the Investigational Drugs Journal|May 10, 2008
ATP site-directed kinase inhibitorsW A Denny
Pharmaceuticals (Basel, Switzerland)|February 26, 2022
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer TherapyWilliam A Denny
Current Medicinal Chemistry|August 13, 2002
Acridine derivatives as chemotherapeutic agentsWilliam A Denny
Cancer Investigation|November 30, 2004
Tumor-activated prodrugs--a new approach to cancer therapyWilliam A Denny
Pageof 75

Showing results (1-10 of 748) with videos related to

Sort By:
Pageof 75
Future Medicinal Chemistry|April 13, 2021
Inhibitors of F<sub>1</sub>F<sub>0</sub>-ATP synthase enzymes for the treatment of tuberculosis and cancerWilliam A Denny
Journal of Biomedicine & Biotechnology|April 11, 2003
Prodrugs for Gene-Directed Enzyme-Prodrug Therapy (Suicide Gene Therapy)William A. Denny
The New Zealand Medical Journal|March 30, 2001
Turning off growth signals in tumours: a new approach to cancer chemotherapyW A Denny
Idrugs : the Investigational Drugs Journal|December 1, 2004
American Association for Cancer Research - 93rd Annual Meeting. Investigational kinase inhibitors. 6-10 April 2002, San Francisco, CA, USAWilliam A Denny
Expert Opinion on Investigational Drugs|July 5, 2005
Topoisomerase targeted agents - chemistry to chemotherapyW A Denny
The Lancet. Oncology|March 22, 2002
The role of hypoxia-activated prodrugs in cancer therapyW A Denny
Idrugs : the Investigational Drugs Journal|May 10, 2008
ATP site-directed kinase inhibitorsW A Denny
Pharmaceuticals (Basel, Switzerland)|February 26, 2022
Nitroaromatic Hypoxia-Activated Prodrugs for Cancer TherapyWilliam A Denny
Current Medicinal Chemistry|August 13, 2002
Acridine derivatives as chemotherapeutic agentsWilliam A Denny
Cancer Investigation|November 30, 2004
Tumor-activated prodrugs--a new approach to cancer therapyWilliam A Denny
Pageof 75